Financial analysis of Pfizer Inc. stock ahead of its earnings release. PFE faces significant headwinds from patent expiries, click for my updated look at the stock.

The lawsuit alleges the price increases EpiPen, used to treat severe allergic reactions, prevented other similar medications ...

U.S. drugmaker Pfizer PFE.N is going “all in” to develop its experimental obesity drug and has been recruiting more experts in that area, Chief Executive Officer Albert Bourla said at the JPMorgan ...

These four top dividend stocks offer dependable passive income streams and solid total return, and they are too cheap to ...

Pills are subject to negotiation sooner than complex injectable drugs under the law ... Other drugs up for 2027 price ...

Through the drug, Pfizer aims to offer patients a more convenient alternative to injectable drugs — Eli Lilly's Zepbound and Novo Nordisk's — that currently dominate the weight-loss treatment ...

Here are three dividend stocks that retirees can buy with confidence as they offer recurring, dependable payouts and a degree ...

BURLINGAME, CA, UNITED STATES, January 9, 2025 /EINPresswire / -- Latest Report, titled“Middle East And Asia Injectable Drugs Market” Trends, Share, Size, Growth, Opportunity and Forecast 2025 ...

Pfizer targets $4 billion in operational savings ... Above all, the obesity drug market is already crowded with established injectables and emerging orals. The efficacy, tolerability, and speed ...

Pfizer’s top-selling breast cancer drug Ibrance also on ... Pills are subject to negotiation sooner than complex injectable ...

Acquiring an injectable GLP-1 drug would not be in Pfizer's interest because "probably it's a little bit too late," Bourla said, referring to Wegovy and Zepbound's class of treatments that target ...